State-of-the-art management of locally advanced head and neck cancer

por Seiwert, T Y, Cohen, E E W
Publicado 2005

Molecular targeted therapies in head and neck cancer - An update of recent developements -

por Goerner, Martin, Seiwert, Tanguy Y, Sudhoff, Holger
Publicado 2010

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma

por Adashek, Jacob J., Sapkota, Surendra, de Castro Luna, Rodrigo, Seiwert, Tanguy Y.
Publicado 2023

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma o...

por Rieke, Damian T., Ochsenreither, Sebastian, Klinghammer, Konrad, Seiwert, Tanguy Y., Klauschen, Frederick, Tinhofer, Inge, Keilholz, Ulrich
Publicado 2016

Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic...

por Xu, Yimin, Zhu, Gangcai, Maroun, Christopher A., Wu, Irene X. Y., Huang, Donghai, Seiwert, Tanguy Y., Liu, Yong, Mandal, Rajarsi, Zhang, Xin
Publicado 2021

Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer

por Yang, Xinan, Regan, Kelly, Huang, Yong, Zhang, Qingbei, Li, Jianrong, Seiwert, Tanguy Y., Cohen, Ezra E. W., Xing, H. Rosie, Lussier, Yves A.
Publicado 2012

Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer

por Ren, Lili, Matsuda, Tatsuo, Deng, Boya, Kiyotani, Kazuma, Kato, Taigo, Park, Jae-Hyun, Seiwert, Tanguy Y., Vokes, Everett E., Agrawal, Nishant, Nakamura, Yusuke
Publicado 2017

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)

por Seiwert, T. Y., Fayette, J., Cupissol, D., del Campo, J. M., Clement, P. M., Hitt, R., Degardin, M., Zhang, W., Blackman, A., Ehrnrooth, E., Cohen, E. E. W.
Publicado 2014

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

por Pai, Sara I., Faivre, Sandrine, Licitra, Lisa, Machiels, Jean-Pascal, Vermorken, Jan B., Bruzzi, Paolo, Gruenwald, Viktor, Giglio, Raul E., Leemans, C. René, Seiwert, Tanguy Y., Soulieres, Denis
Publicado 2019

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma

por Rolle, Cleo E., Tan, Yi-Hung Carol, Seiwert, Tanguy Y., Vora, Sapana, Kanteti, Rajani, Hasina, Rifat, Carey, George B., Surati, Mosmi, Weichselbaum, Ralph R., Lingen, Mark W., Vokes, Everett E., Salgia, Ravi
Publicado 2016

MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer

por Faoro, Leonardo, Cervantes, Gustavo M., Ferguson, Benjamin D., Seiwert, Tanguy Y., Yala, Soheil, Vigneswaran, Wicki T., Westerhoff, Maria, Tretiakova, Maria S., Ferguson, Mark K., Moura, Glaci L., Husain, Aliya N., Vokes, Everett E., Salgia, Ravi
Publicado 2009

DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer

por Seiwert, Tanguy Y., Wang, XiaoZhe, Heitmann, Jana, Villegas-Bergazzi, Vivian, Sprott, Kam, Finn, Stephen, O'Regan, Esther, Farrow, Allan D., Weichselbaum, Ralph R., Lingen, Mark W., Cohen, Ezra E. W., Stenson, Kerstin, Weaver, David T., Vokes, Everett E.
Publicado 2014

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

por Haddad, Robert I, Seiwert, Tanguy Y, Chow, Laura Q M, Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P, Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Albright, Andrew, Mogg, Robin, Ayers, Mark, Huang, Lingkang, Lunceford, Jared, Cristescu, Razvan, Cheng, Jonathan, Mehra, Ranee
Publicado 2022

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

por Mehra, Ranee, Seiwert, Tanguy Y., Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P., Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Geva, Ravit, Chung, Hyun Cheol, Lin, Chia-Chi, Aurora-Garg, Deepti, Ray, Archana, Pathiraja, Kumudu, Cheng, Jonathan, Chow, Laura Q. M., Haddad, Robert
Publicado 2018

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

por Aggarwal, Charu, Saba, Nabil F., Algazi, Alain, Sukari, Ammar, Seiwert, Tanguy Y., Haigentz, Missak, Porosnicu, Mercedes, Bonomi, Marcelo, Boyer, Jean, Esser, Mark T., Cheng, Lily I., Agrawal, Sonia, Jennings, Emily C., Durham, Nicholas M., Fraser, Karl, Lissa, Delphine, Gong, Maozhen, Ceaicovscaia, Natalia, Gascó Hernández, Amaya, Kumar, Rakesh
Publicado 2023

Persistent mutation burden drives sustained anti-tumor immune responses

por Niknafs, Noushin, Balan, Archana, Cherry, Christopher, Hummelink, Karlijn, Monkhorst, Kim, Shao, Xiaoshan M., Belcaid, Zineb, Marrone, Kristen A., Murray, Joseph, Smith, Kellie N., Levy, Benjamin, Feliciano, Josephine, Hann, Christine L., Lam, Vincent, Pardoll, Drew M., Karchin, Rachel, Seiwert, Tanguy Y., Brahmer, Julie R., Forde, Patrick M., Velculescu, Victor E., Anagnostou, Valsamo
Publicado 2023

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 E...

por Chow, Laura Q.M., Haddad, Robert, Gupta, Shilpa, Mahipal, Amit, Mehra, Ranee, Tahara, Makoto, Berger, Raanan, Eder, Joseph Paul, Burtness, Barbara, Lee, Se-Hoon, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Weiss, Jared, Geva, Ravit, Lin, Chia-Chi, Chung, Hyun Cheol, Meister, Amy, Dolled-Filhart, Marisa, Pathiraja, Kumudu, Cheng, Jonathan D., Seiwert, Tanguy Y.
Publicado 2016

Biomarkers predictive of response to pembrolizumab in head and neck cancer

por Pfister, David G., Haddad, Robert I., Worden, Francis P., Weiss, Jared, Mehra, Ranee, Chow, Laura Q. M., Liu, Stephen V., Kang, Hyunseok, Saba, Nabil F., Wirth, Lori J., Sukari, Ammar, Massarelli, Erminia, Ayers, Mark, Albright, Andrew, Webber, Andrea L., Mogg, Robin, Lunceford, Jared, Huang, Lingkang, Cristescu, Razvan, Cheng, Jonathan, Seiwert, Tanguy Y., Bauml, Joshua M.
Publicado 2022

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

por Yap, Timothy A., Gainor, Justin F., Callahan, Margaret K., Falchook, Gerald S., Pachynski, Russell K., LoRusso, Patricia, Kummar, Shivaani, Gibney, Geoffrey T., Burris, Howard A., Tykodi, Scott S., Rahma, Osama E., Seiwert, Tanguy Y., Papadopoulos, Kyriakos P., Blum Murphy, Mariela, Park, Haeseong, Hanson, Amanda, Hashambhoy-Ramsay, Yasmin, McGrath, Lara, Hooper, Ellen, Xiao, Xiaoying, Cohen, Heather, Fan, Martin, Felitsky, Daniel, Hart, Courtney, McComb, Rachel, Brown, Karen, Sepahi, Ali, Jimenez, Judith, Zhang, Weidong, Baeck, Johan, Laken, Haley, Murray, Richard, Trehu, Elizabeth, Harvey, Christopher J.
Publicado 2022